Breckenridge Announces Approval of Methscopolamine Bromide Tablets
BOCA RATON, Fla., Dec. 9, 2011 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced that the U.S. Food and Drug Administration granted final approval for their Abbreviated New Drug Application (ANDA) for Methscopolamine Bromide Tablets. Methscopolamine Bromide Tablets are AB rated to Pamine®, a prescription medicine that is used as adjunctive therapy for the treatment of peptic ulcers. Pamine® is marketed by Kenwood Therapeutics. The current market is approximately $7M, based on industry sales data. The product will be available to customers in early 2012.
SOURCE Breckenridge Pharmaceutical, Inc.